ERBB2 and breast carcinoma: Mutations in the p110α subunit (PIK3CA) have been found in around 40% of HR+/HER2– or HER2+ advanced breast cancer tumors and around 9% of TNBC tumors (Cancer Genome Atlas Network, 2012; Guerrero-Zotano et al., 2016).